• VaxThera, whose objective is to foster sanitary sovereignty in the country, is recognized as the most innovative new business in Seguros SURA in 2021.
• SURA climbs eight positions in this measurement of Colombia’s National Association of Industrialists (Asociación Nacional de Empresarios) which rated 347 organizations.
• VaxThera is making progress in its development of a vaccine against COVID -19 and other diseases that affect Latin America.

August 16, 2022. Colombia’s National Association of Industrialists (Asociación Nacional de Empresarios – ANDI) each year recognizes the efforts, work, and results in the area of innovation in the private sector and does this through its Business Innovation Ranking. In its sixth edition, SURA took second place as the country’s most innovative company, climbing eight positions compared to the measurements in 2021.

This recognition is the result of the creation of VaxThera as a new business to drive the country’s sanitary sovereignty. A new biotechnology company dedicated to the design, research, development, and production of vaccines and biologicals, whose objective is to contribute to Colombia’s and Latin America’s sanitary security and technological independence, with a projected investment of $54 million for its initial phase.

“VaxThera is a 100% Colombian, SURA company, focused on research, development, and innovation of vaccines and biologicals. We aim to become a leader in the country and the region in the area of biotechnology so that Colombia can become a hub for science and technology and a benchmark for Latin America”, said Jorge Emilio Osorio, CEO of VaxThera.

1. Pioneering business in the country: it is the first company focused on designing, developing, and producing vaccines for humans in the country
2. The company has several development platforms: it is a multiplatform company which initially includes two platforms for vaccine development: viral vector, and mRNA.
3. Pipeline for research and new knowledge creation: it focuses on emerging and re-emerging infectious diseases, and on other pathologies that require treatments that may be developed using the same platforms as vaccines, for example, cancer and other chronic diseases.
4. Aligned with the “prosumer” trend in vaccines: another differentiating factor intended to have Colombia go from simple consumer to producer.
5. Use of computer technology in production: this will make it possible to do modelling, simulation, characterization, and analysis of the behavior and genetics of different microorganisms and so identify molecular targets.

For more information, contact:

Eliana Siegert
esiegert@vaxthera.com